Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance
The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management.
As market volatility continues, small-cap stocks are attracting investor attention with groundbreaking technological advancements, biotech breakthroughs, and resource expansion projects . Companies across multiple industries are making major strides, positioning themselves for growth and long-term value creation . Here are some of the most compelling penny stocks that are making headlines
Aditxt (NASDAQADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person Syndrome. Adimune has completed preclinical studies and is preparing for drug substance shipment in March, with clinical trials planned in Germany and an FDA pre-IND meeting anticipated in the second quarter of 2024. ADI-100 is designed to restore immune tolerance without immunosuppression, marking a potential breakthrough in autoimmune disease treatment.
Aditxt, Inc. (NASDAQADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today provided an update on its subsidiary, Adimune, Inc., (“Adimune”) and its progress in advancing ADI-100, an investigational product candidate to be studied in patients with Psoriasis, Type I Diabetes (T1D) and Stiff Person Syndrome.
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
Aditxt (NASDAQADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities LLC as the lead underwriter for its planned initial public offering (IPO), expected in the second half of 2025. The IPO aims to support Pearsanta’s commercialization of its Mitomic® Technology platform for early cancer detection, leveraging mitochondrial DNA biomarkers for non-invasive diagnostics. Funds raised will facilitate the U.S. launch of Laboratory Developed Tests (LDTs) and drive global expansion through regulatory approvals and distribution partnerships.
Aditxt, Inc. (NASDAQADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta’s planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta’s U.S. and international commercial launch efforts and further advance its Mitomic® Technology platform for early cancer detection and diagnosis.
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
